Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic cells are...
Induced Pluripotent Stem Cells01:13

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different types of cells. Ordinarily, cells that have differentiated into a specific cell type are post-mitotic—that is, they no longer divide. However, scientists have found a way to reprogram these mature cells so that they “de-differentiate” and return to an unspecialized, proliferative state. These cells are also pluripotent like embryonic stem cells—able to produce all cell types—and are therefore called induced pluripotent stem...
EPS and iPS Cells in Disease Research01:21

EPS and iPS Cells in Disease Research

Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Automated loss of pulse detection on a consumer smartwatch.

Nature·2025
Same author

Author Correction: Transcriptional characterization of iPSC-derived microglia as a model for therapeutic development in neurodegeneration.

Scientific reports·2024
Same author

Transcriptional characterization of iPSC-derived microglia as a model for therapeutic development in neurodegeneration.

Scientific reports·2024
Same author

Functional evaluation of epilepsy-associated KCNT1 variants in multiple cellular systems reveals a predominant gain of function impact on channel properties.

Epilepsia·2023
Same author

Investigation of SAMD1 ablation in mice.

Scientific reports·2023
Same author

Characterizing the composition of iPSC derived cells from bulk transcriptomics data with CellMap.

Scientific reports·2022

Related Experiment Video

Updated: May 10, 2026

Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery
12:40

Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery

Published on: May 19, 2018

Integrating human pluripotent stem cells into drug development.

Sandra J Engle1, Dinesh Puppala

  • 1Pharmacokinetics, Dynamics and Metabolism, Pfizer, Eastern Point Road, Groton, CT 06340, USA. sandra.j.engle@pfizer.com

Cell Stem Cell
|June 11, 2013
PubMed
Summary

Integrating human pluripotent stem cell-derived cells into early drug discovery can improve clinical translation. However, challenges hinder the widespread adoption of these physiologically relevant in vitro assays.

More Related Videos

Integration Free Derivation of Human Induced Pluripotent Stem Cells Using Laminin 521 Matrix
10:48

Integration Free Derivation of Human Induced Pluripotent Stem Cells Using Laminin 521 Matrix

Published on: July 7, 2017

Automated Production of Human Induced Pluripotent Stem Cell-Derived Cortical and Dopaminergic Neurons with Integrated Live-Cell Monitoring
09:34

Automated Production of Human Induced Pluripotent Stem Cell-Derived Cortical and Dopaminergic Neurons with Integrated Live-Cell Monitoring

Published on: August 6, 2020

Related Experiment Videos

Last Updated: May 10, 2026

Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery
12:40

Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery

Published on: May 19, 2018

Integration Free Derivation of Human Induced Pluripotent Stem Cells Using Laminin 521 Matrix
10:48

Integration Free Derivation of Human Induced Pluripotent Stem Cells Using Laminin 521 Matrix

Published on: July 7, 2017

Automated Production of Human Induced Pluripotent Stem Cell-Derived Cortical and Dopaminergic Neurons with Integrated Live-Cell Monitoring
09:34

Automated Production of Human Induced Pluripotent Stem Cell-Derived Cortical and Dopaminergic Neurons with Integrated Live-Cell Monitoring

Published on: August 6, 2020

Area of Science:

  • Biomedical research
  • Stem cell biology
  • Drug discovery and development

Background:

  • Physiologically relevant in vitro assays are crucial for successful drug discovery.
  • Human pluripotent stem cell (hPSC)-derived cells offer a promising model for human physiology.
  • Current implementation of these advanced assays in drug discovery pipelines is slower than expected.

Purpose of the Study:

  • To highlight the importance of incorporating in vitro-differentiated human pluripotent stem cell (IVD hPSC)-derived cells into early drug discovery.
  • To discuss the key drivers and necessities for adopting IVD hPSCs in drug development.
  • To identify and analyze the challenges impeding the broader use of IVD hPSCs.

Main Methods:

  • This perspective reviews current literature and expert insights on IVD hPSC applications.
  • It analyzes the potential benefits and obstacles related to integrating these cells into drug discovery workflows.
  • The discussion focuses on the translation of preclinical findings to clinical success.

Main Results:

  • IVD hPSCs present a significant opportunity to enhance the predictive power of preclinical drug testing.
  • Despite their potential, several technical, logistical, and regulatory hurdles remain.
  • Overcoming these challenges is essential for realizing the full impact of IVD hPSCs.

Conclusions:

  • Incorporating IVD hPSCs into drug discovery is imperative for improving clinical translation rates.
  • Addressing the identified challenges is critical for accelerating the adoption and maximizing the benefits of these advanced in vitro models.
  • Future efforts should focus on standardization, validation, and integration strategies for IVD hPSCs.